Last reviewed 2026-04-20 · How we verify

Heparin SC

Heparin SC, marketed by Columbia University, is a well-established anticoagulant with a key composition patent expiring in 2028. The drug's primary strength lies in its long-standing market presence and recognized efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
• REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (PHASE3)
• A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
• Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention (PHASE4)
• The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD (NA)
• A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants (PHASE2)
• Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Heparin SC CI brief — competitive landscape report
• Heparin SC updates RSS · CI watch RSS
• Columbia University portfolio CI